Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. Show more

Location: 75 State Street, Boston, MA, 02109, United States | Website: https://www.finchtherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

20.1M

52 Wk Range

$1.27 - $15.85

Previous Close

$12.75

Open

$12.75

Volume

305

Day Range

$12.75 - $12.75

Enterprise Value

34.15M

Cash

16.04M

Avg Qtr Burn

-4.514M

Insider Ownership

13.39%

Institutional Own.

0.47%

Qtr Updated

06/30/24